Payment overview · 2025
General Payments
$1,592.68
86 reported records · 13 companies
Healthcare provider profile · identity verified
Arron Wright, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · PHILADELPHIA, PA · NPI 1568177988
Verified facts
What the public records show
CMS Open Payments records show Arron Wright, APRN received $1,592.68 in general payments during 2025 across 86 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $415.05 | 26.1% | 20 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $291.11 | 18.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $260.91 | 16.4% | 19 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.45 | 9.2% | 14 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $105.89 | 6.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.51 | 4.6% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $71.05 | 4.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $54.99 | 3.5% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $54.84 | 3.4% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $50.76 | 3.2% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.39 | 2.2% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $16.48 | 1.0% | 1 | 2025 |
| Vertical Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.25 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,592.68 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $488.56 | 24 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $291.11 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $260.91 | 19 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $146.45 | 14 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $105.89 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $55.85 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $54.99 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $54.84 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $50.76 | 4 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Relexxii Normalized: relexxii |
Drug | Vertical Pharmaceuticals, LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA Normalized: invega |
Drug | Janssen Pharmaceuticals, Inc | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 189 | 11 |
| Sertraline Hcl | Sertraline Hcl | 86 | suppressed |
| Bupropion Xl | Bupropion Hcl | 71 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 67 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,592.68 · 86 records | Otsuka America Pharmaceutical, Inc. | Adzenys XR-ODT, Azstarys, CAPLYTA, INVEGA, Jornay PM, LYBALVI, Qelbree, REXULTI, Relexxii, SPRAVATO, TRINTELLIX, VRAYLAR, ZURZUVAE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error